Covid-19 impact in neurological or psychiatric manifestations in patients with Covid-19 infection

patients initially followed for a neurological or psychiatric pathology, suffering from a Covid-19 infection

Neurologic Manifestations

Psychiatric Disorders

COVID-19

CoCo-Neurosciences project is described on the Paris Brain Institute website

Hôpital Pitié Salpétrière

Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders (CoCo-Neurosciences)

Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders: An Observational Study of the Covid-19 Neurological and Psychiatric Manifestations

Frequency of central or peripheral neurological or psychiatric symptoms observed in patients with COVID-19

Impact on neurological or psychiatric disease trajectories assessed by severity scores or subjective progression (improved, stable, impaired) during and after COVID-19 pathology in patients with pre-existing neurological and psychiatric diseases

Assistance Publique - Hôpitaux de Paris

Ivermectin 200 mcg/kg once orally on empty stomach plus Nitazoxanide 500 mg twice daily orally with meal for 6 days

Ivermectin plus Nitazoxanide

Standard Care

Ivermectin and Nitazoxanide Combination Therapy for COVID-19

Clinical Trial Evaluating Safety and Efficacy of Ivermectin and Nitazoxanide Combination as Adjuvant Therapy in COVID-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope

improved breaths per minute for the patients

Serum iron in microgram/dL of the patients

Serum ferritinin microgram/L of the patients

International normalized ratio "INR" for prothrombin time of 2

CBC for lymphocyte count in cells/microliter

Mortality rate [number of dead patients/total number of treated patients]

Prof. Dr. Kamal Mohammed Okasha

Vice-President of Postgraduate Studies and Research Affairs

Tanta University

This study will be a double blind randomized controlled parallel study

Chikungunya Virus Infection

Anti-CHIKV immunoglobulins (CHIKVIg) were purified after the Tégéline manufacturing process from a pool of 583 plasma samples from donors in the convalescent phase of CHIKV infections. Anti-CHIKV hyper immune intravenous immunoglobulin (50 mg/ml) is prepared as a powder to be reconstituted. The therapeutic regimen will consist of 2 doses of 0.5 g/kg 12 hours apart.

anti-CHIKV hyperimmune immunoglobulins

Centre Hospitalier de la Basse-Terre

Centre Hospitalier de Cayenne "Andrée ROSEMON"

CHU de Martinique

Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins

Prevention of Chikungunya Infection in Neonates: Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins

The primary endpoint will measure tolerability and safety of anti-CHIKV hyperimmune IVIG. It will be evaluated in all enrolled neonates and will be based on the occurrence of the following events:
patent ductus arteriosus,
ulceronecrotizing enterocolitis,
pulmonary hemorrhage,
tachycardia, hypotension, decreased O2 saturation during anti-CHIKV IVIG infusion,
hemolytic anemia,
fluid overload, as indicated by hyponatremia and/or ascites.

The following secondary endpoints will be evaluated only in neonates born to mothers who had a definite CHIKV-infection.
Neonates will be classified in one of the following 3 categories:
Neonatal CHIKV clinical disease:
Clinical symptoms consistent with acute CHIKV infection
Demonstration of infection based on CHIKV IgM seroconversion and/or identification of CHIKV viremia (positive CHIKV qRT-PCR at Day 3),
Neonatal CHIKV asymptomatic infection:
Absence of any symptom consistent with CHIV infection
Demonstration of infection based on CHIKV IgM seroconversion and/or identification of CHIKV viremia (positive CHIKV qRT-PCR at Day 3),
Neonatal CHIKV infection excluded:
Absence of CHIKV IgM seroconversion.
Below is an indicative list of symptoms that are consistent with Chikungunya infection in neonates:
Skin rash, severe desquamative disorder, bullous dermatitis,
Acral edema
Symptoms of encephalopathy/encephalitis : stupor, seizures, impaired sucking

viremia/seizures

Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders (CoCo-Neurosciences)

Ivermectin and Nitazoxanide Combination Therapy for COVID-19

Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins

科学支持的最完整的草药数据库